Jennifer Ziolkowski resigns from CFO post at Solid Biosciences; Sean Bohen's Olema Oncology adds Sandra Horning to board of directors
→ Jennifer Ziolkowski has decided to step down from Ilan Ganot’s team at Solid Biosciences “to pursue a new career opportunity,” according to an SEC document filed Friday. Ziolkowski will continue to be Solid’s CFO until Jan. 29, 2021. The day after she announced her resignation at the company, the Duchenne muscular dystrophy biotech entered into a consulting agreement with Danforth Advisors, at which point Danforth managing partner Stephen DiPalma was named interim CFO. DiPalma has been a CFO before at Forum Pharmaceuticals and Aquila Biopharmaceuticals, and he founded Catalyst Oncology and Athena Diagnostics.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 94,300+ biopharma pros reading Endpoints daily — and it's free.